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for each month during the ﬁrst year following transplan-
tation took into account only direct costs arising from
transplantectomy (€3,153, procedural rate plus daily 
hospital rate) and dialysis (€3,687 monthly, Kupsch et al.
1998). RESULTS: Based on these data, the average
annual costs of a graft loss are calculated. Consequently,
an average patient treated with cyclosporine brand med-
ication leads to additional annual costs of €4,239 due to
graft loss. In patients treated with a generic formulation
these costs amount to €7,832. The resulting cost dif-
ferential of €3,593 per year implies that a generic
cyclosporine formulation would have to be at least 61%
cheaper than a brand regimen (currently €5,675 p.a.) in
order to be at least cost neutral. CONCLUSION: Focus-
ing only on direct costs of graft loss not including e.g.
rescue medication, the above calculation is extremely con-
servative. Cost savings potentially achievable by means of
a generic treatment regimen will most likely be consumed
by signiﬁcant costs resulting from graft loss unless the
generic is more than 61% cheaper than brand medica-
tion. This ratio will worsen considerably if the costs for
retransplantation are taken into account.
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OBJECTIVE: An economic model was developed to 
estimate the comparative cost-effectiveness of treating
unstable bladder (UB) in Belgium with alternative drug
treatments and no treatment. The model uses a one-year
timeframe and the payer (e.g., Riziv/INAMI, Sickness
funds) perspective. METHODS: The study population
included patients seeking UB treatment and was divided
into successfully treated patients (STP) and patients
failing treatment (PFT). The percentage of STP was cal-
culated from clinical efﬁcacy adjusted by annual persis-
tency. For each group of patients, direct and indirect costs
were identiﬁed, including costs for drugs, incontinence
pads, physician visits, lab tests/diagnostics, and associated
comorbidities. Resource utilization and costs were
obtained from literature, the National Health Insurance
System, Ofﬁcial Public Price Ministry Economic
Affairs/Pharmaceutical Tariﬁcation, clinical trials, and
expert medical panels. RESULTS: The prevalence of UB
sufferers in Belgium was estimated to be 3% in 2002
(approximately 303,000 people), with only 30% of those
patients seeking treatment (approximately 1% of the
Belgian population). STP used fewer pads per day, visited
physicians less frequently, had fewer lab tests/diagnostics,
and experienced fewer comorbidities than PFT. Cost
drivers in the model were comorbidities and physician
visits. Tolterodine sustained-release (TSR) had compara-
ble efﬁcacy to oxybutynin, but persistence on therapy was
higher for TSR. Therefore, effectiveness was higher for
TSR versus oxybutynin (37% for TSR, 10% for oxybu-
tynin). Effectiveness was considered 0% for no treatment.
Cost per STP was €1,167 for TSR and €2,181 for oxy-
butynin. Sensitivity analyses varying efﬁcacy and persis-
tency by 10% still resulted in a lower cost per STP for
TSR. TSR had an incremental cost-effectiveness of €816.
The “no treatment” group demonstrated the highest non-
drug costs while providing no efﬁcacy. CONCLUSION:
Tolterodine sustained-release is a more cost-effective
treatment than oxybutynin in treating UB as measured by
cost per successfully treated patient in Belgium.
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OBJECTIVES: Several researchers have estimated the
cost-effectiveness (CE) of long-acting forms of tolterodine
(TOL) and oxybutynin (OXY) in overactive bladder
(OAB). Typically, it’s assumed that effectively treated
patients consume fewer resources, including incontinence
pads, physician visits, laboratory tests, and costs related
to comorbid conditions. Claims analyses have shown a
link between the presence of OAB and higher medical
costs; however, no prospective studies have evaluated the
effect of treatment on resource consumption, and drug
acquisition cost (DAC) continues to be the focus for many
decision-makers. A head-to-head patient outcome trial
comparing TOL and OXY was recently completed, 
the Antimuscarinic Clinical Effectiveness Trial (ACET);
however, resource consumption wasn’t collected. Our
objective was to determine the CE of TOL 4mg and OXY
10mg based on DAC and effectiveness data from ACET.
METHODS: The primary effectiveness endpoint in
ACET was patient perception of improvement in their
bladder condition after eight weeks of treatment. Results
showed that 70% of TOL patients and 60% of OXY
patients reported improvement in their bladder condition
at 8 weeks. Dropout rates were 11.6% and 20.5% for
TOL and OXY, respectively. We assumed dropouts com-
pleted four weeks of treatment. The daily AWP cost of
TOL 4mg and OXY 10mg was $2.7967 and $2.6875,
respectively. RESULTS: For every 100 patients treated
with TOL and OXY, DAC is $14,752.98 and
$13,507.38, respectively. The cost per effectively treated
patient for TOL is $210.76 and $225.12 for OXY. The
incremental CE for TOL is $124.56 per additional effec-
tively treated patient. CONCLUSIONS: When only DAC
is considered, TOL is more cost-effective than OXY. If
effectively treated patients do consume fewer resources,
then the CE of TOL should be even better. Determining
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the CE of OAB treatments isn’t this simple, however, and
further research is needed to assess changes in resource
consumption due to treatment.
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OBJECTIVES: To compare the estimated ﬁrst-line treat-
ment costs of extended-release tolterodine versus con-
trolled-release oxybutynin in patients with overactive
bladder patients (OAB). METHODS: Data from a 
randomized clinical trial (Curr Med Res Opin 2002;
18:177–184), showing greater improvement in bladder
condition for patients taking extended-release tolterodine
compared to controlled-release oxybutynin (70% vs.
60% in all patients, 75% vs. 54% in patients with prior
therapy, and 69% vs. 61% in treatment naïve patients),
was used to conduct the analyses. The analysis input trial
outcomes into an existing decision analysis model that
had shown extended-release tolterodine was 6.3% less
expensive than controlled-release oxybutynin in terms of
the cost of treatment. Analyses were constructed from the
payer perspective; all costs are given in 2000 U.S. dollars.
RESULTS: The decision analysis model yielded results
that ranged between a 5.7% and 7.0% total cost of 
treatment advantage for extended-release tolterodine in
the treatment of all patients. This cost advantage 
was 5.1%–6.3% for treatment-naïve patients and
8.9%–10.8% for previously treated patients. The varia-
tion in the results depended on the model timeframe
chosen (12, 14, or 16 weeks). Sensitivity analyses showed
these results to be stable. CONCLUSIONS: Results from
these analyses conﬁrm earlier studies that, for patients
with OAB and initiating long-acting pharmacologic
therapy in the primary care setting, treatment with
extended-release tolterodine is less costly than treatment
with controlled-release oxybutynin. Additional studies
directly comparing these treatment alternatives are
needed to further conﬁrm these results.
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OBJECTIVES: Since satisfaction for telemedicine is ill-
deﬁned (Mair, 2000) and no standard measurement tool
is available, we developed a self-administered Question-
naire of the Satisfaction for Telemedicine (QueST).
METHODS: Domains of satisfaction were: 1) global 
satisfaction; 2) user-friendliness; 3) relationship with the
medical center; 4) coping; 5) everyday life; 6) expectations
about telemedicine; and 7) detailed judgment. Answers
were provided through a 4–5 degrees Likert scale; the
overall score was standardized to a maximum value of
100. After a probe technique, the ﬁnal QueST was admin-
istered to 26 patients on telemonitoring (transmission 
of subjective/objective data to an automatic call center 
or web server) for peritoneal dialysis or heart failure.
RESULTS: Mean age of the patients was 57.3 years
(range 43–74); 81% were males. Electronic devices 
(cellular phone or teletext) were daily used by 73% of the
patients, but computer by only 34% of them. Mean sat-
isfaction score was 72 (48–91): 29% of the patients were
highly satisﬁed with telemedicine either by considering
those with an overall score >= 80 or by assessing the
answer in the ﬁrst domain. However, a detailed elicita-
tion of patients judgement on telemedicine showed that
60% of them were very satisﬁed with it. Some users
(24%) declared to have some practical difﬁculties with
telemedicine but 88% of them expected a future beneﬁt
from telemedicine. Both the relations with the referral
center, quality of daily life and coping ability improved
during the period on telemedicine in 73%, 77%, 81% of
the patients, respectively. Willingness to pay for one year
of telemedicine was on average €81: 22% of the patients
were willing to pay for more than €90. CONCLUSIONS:
Acceptability of telemedicine is high and its impact over
the perceived quality of care is relevant. Nevertheless,
patients are willing to have this service included into their
usual health care with no or little extra costs. From the
patients perspective, telemedicine should be implemented
by the National Health Care System.
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OBJECTIVE: To evaluate the role of treatment approach
(CHD or CAPD) on the self-perception of QoL in uremic
patients. Cross-sectional matched pair study of CHD 
and CAPD subjects. METHODS: Sixty-two matched
pairs of patients (30M and 32F), median age 59 years
were studied. The CHD and CAPD groups were similar
for demographic and social variables. Higher percentage
of patients with diuresis >500ml/die and hypertension
were registred in CAPD patients. Nutritional Status was
